Counting down to The Last Mile panel event Aspen Ideas Health today. Join us at 11:10am in the East Lawn Tent – we’ll unpack barriers to vaccination access and uptake at both global and local community levels. #AspenIdeasHealth

Such a great panel today with Lauren Smith (CDC Foundation), Darrell Gray, II, MD, MPH, FACG and @lorirosebenson, moderated by John Trizzino🇮🇱 on the “Last Mile” of access to allow vaccines to make a difference. Like Darrell said, ”Change happens at the speed of trust.” I couldn’t agree more! #AspenIdeasHealth

TODAY: Novavax participated in the FDA VRBPAC meeting which resulted in a 19-2 vote to recommend inclusion of a SARS-CoV-2 Omicron component for #COVID19booster vaccines in the U.S. beginning this fall. bit.ly/3bzZ0ku

Novavax Statement on Prototype Vaccine’s Broad Immune Responses and Accelerated Focus on Omicron BA.4/5 as Recommended by the FDA: bit.ly/3nuyKLe

New: The European Commission has approved the expanded conditional marketing authorization for the Novavax #COVID19Vaccine in the European Union for adolescents aged 12 through 17. Learn more: bit.ly/3afV48l

U.S. Government Secures 3.2 Million Doses of Novavax #COVID19Vaccine: bit.ly/3at2CVv

We’ve got big news. Our protein-based #COVID19vaccine is now authorized for 18+ primary series under emergency use in the United States. [🧵1 of 2] Read more: ir.novavax.com/2022-07-13-U-S…

U.S. CDC Advisory Committee Unanimously Recommends Novavax COVID-19 Vaccine, Adjuvanted as a Primary Series for Individuals Aged 18 and Older: ir.novavax.com/2022-07-19-U-S…

The Novavax COVID-19 Vaccine, Adjuvanted is now on vaccines.gov. Visit the site to enter your zip code and find the location nearest you. Locations will continually update, so check back if there is not a location near you.

NEW: Novavax submitted our application to the U.S. FDA for Emergency Use Authorization for Novavax #COVID19Vaccine as a booster, if authorized, Novavax’ vaccine would be the first protein-based COVID-19 booster for adults. Learn more: ir.novavax.com/2022-08-15-Nov… (1/2)

NEW: The Novavax #COVID19Vaccine has received emergency use authorization (EUA) from the U.S. FDA to provide a two-dose primary series in adolescents aged 12 -17, in addition to the existing 18+ EUA. (🧵1 of 2) Learn more: ir.novavax.com/2022-08-19-U-S…

Today, we authorized the Novavax COVID-19 Vaccine, Adjuvanted for use as a first booster dose for individuals 18 & older at least 6 months after completion of primary vaccination with an FDA-approved or authorized COVID-19 vaccine. fda.gov/emergency-prep…

I recently visited the UK for the Jefferies London Healthcare Conference. I always look forward to this annual opportunity to meet investors and discuss Novavax’ plans for the future! I think it was a very productive meeting this year. #Jefferies

I can’t wait to have John Jacobs and his in-depth industry experience join the team. Much more to come. Stan – Thank you for your steadfast leadership. You’ve left a lasting legacy on global public health.

If you’re at @JPMorgan Healthcare Conference, we hope you’ll join Novavax CEO Stan Erck & JPM's Eric Joseph, Ph.D. for our presentation at 5:15pm PST in the Borgia room. Webcast available here: ir.novavax.com/41st-Annual-J-… Replay available on Novavax.com/Events following. #JPM23

Today, we welcome John Jacobs to the Novavax team. John has already immersed himself in all things Novavax and will be busy meeting with company leaders, employees, and stakeholders in the coming days and weeks. I’m excited to work with you John! Much more to come.

Thanks for having me today for a great conversation!

Honored to join the Maryland Technology Council's esteemed Board of Directors! I am grateful for the opportunity to contribute to tech innovation, collaborate with industry leaders, and drive growth in this vibrant community. #techadvancement #Grateful #biotech